INTRODUCTION AND HYPOTHESIS: Interstitial cystitis is a multifaceted medical condition consisting of pelvic pain, urgency, and frequency. Can sacral neuromodulation be successfully utilized for the medium term of ≥ 6 years in interstitial cystitis patients for whom standard drug therapies have failed? METHODS: In our observational, retrospective, case-controlled review (January 2002-March 2004), we sought to discern whether neuromodulation could be successfully implemented with acceptable morbidity rates in interstitial cystitis patients. Thirty-four female patients underwent stage 1 and 2 InterStim placements under a general anesthetic. Simple means and medians were analyzed. RESULTS: Mean pre-op/post-op pelvic pain and urgency/frequency scores were 21.61 ± 8.6/9.22 ± 6.6 (p < 0.01), and mean pre-op/post-op visual analog pain scale (VAPS) were 6.5 ± 2.9/2.4 ± 1.1 (p < 0.01). Median age was 41 ± 14.8 years with a mean follow-up of 86 ± 9.8 months. CONCLUSIONS: With a minimum 6-year follow-up we determined that sacral neuromodulation provides adequate improvement for the symptoms of recalcitrant interstitial cystitis.
INTRODUCTION AND HYPOTHESIS: Interstitial cystitis is a multifaceted medical condition consisting of pelvic pain, urgency, and frequency. Can sacral neuromodulation be successfully utilized for the medium term of ≥ 6 years in interstitial cystitispatients for whom standard drug therapies have failed? METHODS: In our observational, retrospective, case-controlled review (January 2002-March 2004), we sought to discern whether neuromodulation could be successfully implemented with acceptable morbidity rates in interstitial cystitispatients. Thirty-four female patients underwent stage 1 and 2 InterStim placements under a general anesthetic. Simple means and medians were analyzed. RESULTS: Mean pre-op/post-op pelvic pain and urgency/frequency scores were 21.61 ± 8.6/9.22 ± 6.6 (p < 0.01), and mean pre-op/post-op visual analog pain scale (VAPS) were 6.5 ± 2.9/2.4 ± 1.1 (p < 0.01). Median age was 41 ± 14.8 years with a mean follow-up of 86 ± 9.8 months. CONCLUSIONS: With a minimum 6-year follow-up we determined that sacral neuromodulation provides adequate improvement for the symptoms of recalcitrant interstitial cystitis.
Authors: C Lowell Parsons; Jeffrey Dell; Edward J Stanford; Michael Bullen; Bruce S Kahn; Tracy Waxell; James A Koziol Journal: Urology Date: 2002-10 Impact factor: 2.649
Authors: G R Sant; K J Propert; P M Hanno; D Burks; D Culkin; A C Diokno; C Hardy; J R Landis; R Mayer; R Madigan; E M Messing; K Peters; T C Theoharides; J Warren; A J Wein; W Steers; J W Kusek; L M Nyberg Journal: J Urol Date: 2003-09 Impact factor: 7.450
Authors: J Quentin Clemens; Richard T Meenan; Maureen C O'Keeffe Rosetti; Teresa A Kimes; Elizabeth A Calhoun Journal: J Urol Date: 2008-04-18 Impact factor: 7.450
Authors: Amr Mahran; Gina Baaklini; Daisy Hassani; Hassan A Abolella; Ahmed S Safwat; Mandy Neudecker; Adonis K Hijaz; Sangeeta T Mahajan; Steven W Siegel; Sherif A El-Nashar Journal: Int Urogynecol J Date: 2019-03-14 Impact factor: 2.894
Authors: Anne M Suskind; Rodney L Dunn; Samuel R Kaufman; John O L DeLancey; J Quentin Clemens; John T Stoffel; Brent K Hollenbeck Journal: Surg Innov Date: 2013-04-16 Impact factor: 2.058